Identification and functional characterization of a novel surfactant protein A2 mutation (p.N207Y) in a Chinese family with idiopathic pulmonary fibrosis

Lv Liu | Jieli Qin | Ting Guo | Ping Chen | Ruoyun Ouyang | Hong Peng | Hong Luo

Department of Respiratory Medicine, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

Correspondence
Hong Luo, No. 139, RenMing Road, FuRong Block, 410011 Changsha, China. Email: luohonghuxi@csu.edu.cn

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81470202 and 81770002

Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a serious disorder with a high mortality rate worldwide. It is characterized by irreversible scarring of the lung parenchyma resulting from excessive collagen production by proliferating fibroblasts/myofibroblasts. Previous studies have revealed that mutations in surfactant protein-related genes and telomerase complex genes are crucial underlying genetic factors.

Methods: In this study, we enrolled a family with IPF from the central southern region of China. Whole-exome sequencing was employed to explore candidate genes in this family. Real-time PCR and western blotting were used to study the functions of the identified mutations in vitro.

Results: A novel mutation (NM_001098668.4: c.619A>T; NP_001092138.1: p.N207Y) in surfactant protein A2 (SFTPA2), having not been previously reported to be a mutation, was identified and co-separated with all affected individuals in the IPF family. Functional research further revealed that the novel mutation affects the secretion of SFTPA2 protein and induces endoplasmic reticulum stress as well as apoptosis in A549 cells.

Conclusion: We are confident that this novel mutation (NM_001098668.4: c.619A>T; NP_001092138.1: p.N207Y) in SFTPA2 is the genetic mutation of the IPF family. Our study not only confirms the importance of SFTPA2 in IPF but also expands the spectrum of SFTPA2 mutations and contributes to the genetic diagnosis and counseling of IPF patients.

Keywords
apoptosis, ER stress, idiopathic pulmonary fibrosis, mutation, SFTPA2
1 | INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a chronic fatal interstitial pulmonary disease characterized by irreversible scarring of the lung parenchyma resulting from excessive collagen production by proliferating fibroblasts/myofibroblasts (Lederer & Martinez, 2018; Martinez et al., 2017). Exercise-induced breathlessness and chronic dry cough are the prominent symptoms (Martinez et al., 2017). The prevalence of IPF is estimated to be slightly higher in men (20.2/100,000) than in women (13.2/100,000) (Richeldi, Collard, & Jones, 2017). The mean age at presentation is 66 and the average life expectancy of IPF patients is only 3 years from diagnosis to death (King & Nathan, 2017).

To date, more than eight genes divided into two groups underlying IPF have been identified. (I) surfactant protein-related genes, including surfactant protein C (SFTPC; OMIM 178620) (Nogee et al., 2002), surfactant protein A2 (SFTPA2; OMIM 178642) (Wang et al., 2009), surfactant protein A1 (SFTPA1; OMIM 178630) (Selman et al., 2003) and ATP-binding cassette transporter A3 (ABCA3; OMIM 601615) (Shulenin et al., 2004); and (II) telomere-related genes, such as telomerase reverse transcriptase (TERT; OMIM 187270) (Armanios et al., 2007), telomerase RNA component (TERC; OMIM 602322) (Vulliamy et al., 2004), poly(A)-specific ribonuclease (PARN; OMIM 604212) (Stuart et al., 2015), and regulator of telomere elongation helicase 1 (RTEL1; OMIM 608833) (Stuart et al., 2015). In addition, the most recent studies indicated that MUC5B, ELMOD2, CSF3R, DSP, and LAMA3 present a statistically significant relationship with IPF (Deng et al., 2018). Current large GWAS data also suggest that almost 30% of IPF cases are caused by common genetic mutations (Fingerlin et al., 2013).

In this study, we analyzed an IPF pedigree from the central southern region of China. An autosomal dominant inheritance pattern was identified in this family. Whole-exome sequencing was employed to detect the pathogenic mutation of the affected individuals.

2 | METHODS

2.1 | Ethical compliance

The study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University and performed in accordance with the principles enshrined in the Declaration of Helsinki. Written informed consent was obtained from the patients.

2.2 | Study population

The Review Board of the Second Xiangya Hospital of Central South University approved this research. All patients gave written informed consent. The clinical data and peripheral blood were collected from the large IPF family (Figure 1a). The final diagnosis of the patients was based on high-resolution computed tomography (HRCT) and/or transbronchial lung biopsy, after referring to the ATS/ERS/ERS/ALAT guidelines published in 2011, which excluded known causes of interstitial lung disease (ILD) (Raghu et al., 2011). At least two experts in pulmonary disease, two radiologists and rheumatologists independently reviewed each patient's clinical data.

2.3 | DNA extraction

Genomic DNA was extracted from peripheral blood lymphocytes of all subjects by using the JetFlex™ Genomic DNA Purification Kit (Invitrogen™).

2.4 | Whole exome sequencing

Whole-exome sequencing was used to analyze the genetic factors of the large IPF family. The proband (II-4), one healthy member (II-1) and an affected member (II-7) were chosen for the whole exome sequencing at the Novogene Bioinformatics Institute (Figure 1b). Agilent SureSelect Human All Exon V6 kits was undertaken to capture the exomes and the sequencing platform was an Illumina HiSeq X-10. The strategies for data filtering referred to Figure 1c as our previous described (Liu & Luo, 2018).

2.5 | Cell culture

The A549 cell line was purchased from the Advanced Research Center of Central South University and maintained at 37°C in a humidified, 5% CO2-controlled atmosphere in medium/RPMI-160 medium supplemented with 10% fetal bovine serum, 50 IU/ml penicillin, 50 μg/ml streptomycin, and glutamine.

2.6 | Mutagenesis and cell transfection

The wild-type SFTPA2 CDS (NM_001098668) with a C-terminal HIS-tag in the pEnter was designed by us. The p.N207Y-SFTPA2 missense mutation was constructed
into the above vector using the QuikChange Lightning SiteDirected Mutagenesis Kit (Agilent Technologies). Sanger sequencing was applied to check the constructs. A549 cells were transiently transfected with 2 μg SFTPA2-HIS-pEnter plasmids (WT and/or mutation) using Lipofectamine™ 2000 CD Transfection Reagent (Invitrogen™), according to the manufacturer’s instructions and cultured for 72 hr.

### 2.7 | Real-time qPCR and western blot

Real-time PCR referred to our previous study (Liu & Luo, 2018). For western blotting, one milliliter of cultured medium was removed from each well and centrifuged at 16,000 × g for 10 min at 4°C, and cell protein was extracted using RIPA lysis buffer and the concentration was measured using a BCA kit (Thermo Fisher Scientific). Bis-Tris NuPAGE gels (4%–12%) were used to separate the protein by electrophoresis. Chemiluminescent signals were scanned using a chemiluminescent imaging system (Alpha Innotech). The antibodies against HIS, CHOP, GRP78, Caspase 3, and GAPDH were purchased from Cell Signaling Technology.

### 3 | RESULTS

In this study, we enrolled a large family with IPF and other pulmonary diseases (Figure 1a, Table 1). The proband (II-4),...
a 63-year-old male, showed typical symptoms of cough with little sputum for nearly 4 years. Chest HRCT presented evidence of usual interstitial pneumonitis (UIP) (Figure 1d). Further investigation of the family history revealed that his two brothers (II-5 and II-6) and one sister (II-7) were all diagnosed with IPF according to chest HRCT examination (Figure 1e–g). Both his father (I-1) and one brother (II-3) died from respiratory failure according to the description of the proband. In addition, the III-2 refused to take clinical testing due to far distance from our hospital, but his parents indicated that he (III-2) suffered from lung tuberculosis according to the diagnosis of another hospital several years ago.

Whole-exome sequencing was undertaken to detect the genetic mutation of the family. Basic whole-exome sequencing data are presented in Table S1. After data filtering, as shown in Figure 1b,c, we found 18 candidate mutations including the novel mutation (NM_001098668.4: c.619A>T; NP_001092138.1: p.N207Y) of SFTPA2 (Table 2). Further Sanger sequencing revealed that only the novel mutation of SFTPA2 (NM_001098668.4: c.619A>T; NP_001092138.1: p.N207Y) was present in the affected individuals (II-4, II-5, II-6, II-7, and III-2) and absent in the healthy family members (I-2, II-1, II-2, II-8, III-1, III-4, III-5, III-6, III-7, and III-8) (Figure 1h). This novel mutation, resulting in the substitution of asparagine with tyrosine at position 207 in exon 6 of the SFTPA2 gene, was located in a conserved site (Figure 1i).

As previous studies have not reported this transversion (NM_001098668.4: c.619A>T) as a pathogenic mutation, Wt and the p.N207Y mutant plasmids were constructed and transfected into A549 cell lines to perform functional analysis. After culturing for 72 hr, the culture medium, total cell mRNA, and proteins were collected, respectively. Western blot analysis of the expression of His-SFTPA2 in cell culture medium (the quality of total protein were same in each well) showed that the expression level of Wt was much higher than that of the p.N207Y mutant (Figure 2a), which indicated that the p.N207Y mutation may impair the secretion of SFTPA2. We then performed real-time PCR to analyze the mRNA levels of ER stress-related genes (Adrenomedullin, Adm; Prolyl hydroxylase domain 1 and 3, Egln1/3; Jun dimerization protein 2, Jdp2; CHOP) and apoptosis-related genes (Cell Cycle and Apoptosis Regulatory Protein 1, Ccari1). The results revealed that the expression of endoplasmic reticulum (ER) stress-related genes and apoptosis-related genes was both obviously higher in cells harboring the p.N207Y mutation (Figure 2b), suggesting that the mutation (p.N207Y) of SFTPA2 may induce ER stress and cell apoptosis. Western blot analysis further confirmed this hypothesis (Figure 2c).

According to ACMG guidelines, the novel mutation meets the following criteria from the ACMG guidelines: PS3, PM1, and PM2.

### DISCUSSION

In recent years, an increasing number of studies have discovered that genetic factors play a determinant role in the occurrence and development of IPF in both sporadic and familial cases (Becker, 1989; Spagnolo & Cottin, 2017). It has been proven that up to 20% of people with IPF have another family member with ILD (Fernandez et al., 2012; Garcia-Sancho et al., 2011). In this study, we employed whole-exome sequencing to explore the genetic mutation underlying IPF in a Chinese family. A novel mutation (NM_001098668.4: c.619A>T; NP_001092138.1: p.N207Y) in SFTPA2 was detected in this family. Functional research revealed that this mutation can affect the secretion of the SFTPA2 protein and induce ER stress and apoptosis. Our study is consistent with previous studies showing that pathogenic variations in SFTPA2 play a critical role in IPF by preventing protein secretion and inducing ER stress (Lawson et al., 2008; Spagnolo & Cottin, 2017; Wang et al., 2009).

SFTPA2 is one of several genes encoding pulmonary-surfactant associated proteins. This protein contains three domains: a collagen-like region, a neck and a carbohydrate-recognition domain (Silveyra & Floros, 2013; Wang

| Member | Sex  | Age  | Symptom       | Diagnosis     | HRCT                |
|--------|------|------|---------------|---------------|---------------------|
| I-1    | Male | 62   | Cough, dyspnea| Died from respiratory failure | / |
| II-3   | Male | 50   | Cough, dyspnea| Died from respiratory failure | / |
| II-4   | Male | 63   | Cough, dyspnea| IPF           | UIP                |
| II-5   | Male | 58   | Dyspnea       | IPF           | UIP                |
| II-6   | Male | 37   | Hemoptysis    | IPF           | UIP                |
| II-7   | Female | 56  | Cough, dyspnea| IPF           | UIP                |
| III-2  | Male | 45   | Cough         | Suspected lung tuberculosis | / |

Abbreviations: HRCT, high-resolution computed tomography; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia.

### TABLE 1 Clinic data of familial IPF members
| CHR | POS     | REF | ALT | Gene Name | AA Change | SIFT    | Polyphen2 | MutationTaster |
|-----|---------|-----|-----|-----------|-----------|---------|----------|----------------|
| 2   | 11306069| G   | A   | PQLC3     | PQLC3:NM_001282710:exon2:c.G161A:p.R54Q | 0.18, T | 0.924, D | 0.874, D      |
| 4   | 10886135| T   | G   | CYP2U1    | CYP2U1:NM_183075:exon2:c.T500G:p.F167C | 0, D    | 0.499, P | 1.000, D      |
| 4   | 185618950| G  | T   | CENPU     | CENPU:NM_024629:exon12:c.C994A:p.P332T | 0.26, T | 0.995, D | 1.000, D      |
| 8   | 93027036| G   | A   | RUNX1T1   | RUNX1T1:NM_175636:exon2:c.C128T:p.T43M | 0.16, T | 0.796, P | 1.000, D      |
| 8   | 14557107| G   | A   | TMEM249   | TMEM249:NM_001252404:exon4:c.C514T:p.R172C | 0, D    | 0.06, B  | 1.000, D      |
| 9   | 18928178| C   | T   | FAM154A   | SAXO1:NM_001287049:exon4:c.G1102A:p.E368K | 0.05, D | 0.011, B | 1.000, D      |
| 10  | 81317093| T   | A   | SFTPA2    | SFTPA2:NM_001098668:exon6:c.A619T:p.N207Y | 0.01, D | 0.996, D | 0.986, D      |
| 10  | 93390295| C   | G   | PPP1R3C   | PPP1R3C:NM_005398:exon2:c.G343C:p.D115H | 0.44, T | 0.074, B | 1.000, D      |
| 11  | 93844222| C   | T   | HEPHL1    | HEPHL1:NM_001098677:exon18:c.C3199T:p.R1067C | 0.04, D | 0.717, P | 0.953, D      |
| 12  | 56078934| G   | A   | ITGA7     | ITGA7:NM_001144996:exon25:c.C3334T:p.R1112W | 0.55, T | 0.003, B | 1.000, D      |
| 12  | 12143735| C   | T   | HNF1A     | HNF1A:NM_000545:exon9:c.C1673T:p.P558L | 0.69, T | 0.24, B  | 1.000, D      |
| 17  | 56540247| C   | G   | HSF5      | HSF5:NM_001080439:exon4:c.G1438C:p.A480P | 0.01, D | 0.002, B | 0.997, N      |
| 19  | 1011184 | G   | A   | TMEM259   | TMEM259:NM_001030326:exon10:c.C128T:p.L410F | 0.07, T | 0.987, D | 1.000, D      |
| 19  | 4254397 | C   | T   | CCDC94    | CCDC94:NM_018074:exon4:c.C316T:p.R106W | 0, D     | 0.988, D | 0.872, D      |
| 20  | 61526496| G   | A   | DIDO1     | DIDO1:NM_001193369:exon9:c.C2236T:p.R746C | 0, D     | 0.916, D | 0.981, N      |
| 9   | 990663  | G   | GC   | DMR3      | DMR3:NM_021220:exon2:c.1078dupC:p.Q359fs | —       | —            | 1.000, D      |
| 15  | 29415774| CG  | C   | FAM189A1  | FAM189A1:NM_015307:exon11:c.1387delC:p.R463fs | —       | —            | 1.000, D      |
| 19  | 36258936| CA  | C   | PROSER3   | PROSER3:NM_00139887:exon9:c.1190delA:p.Q397fs | —       | —            | 1.000, D      |

Abbreviations: AB, alternative base identified; B, benign; CHR, Chromosome; D, disease-causing; N, polymorphism; P, probably damaging; POS, position; RB, reference sequence base; T, tolerated.
et al., 2009). Previous studies have demonstrated that mutations in the carbohydrate-recognition domain may result in the formation of an abnormal protein precursor. The abnormal protein accumulates in cells, and ER can cause ER stress (Spagnolo & Cottin, 2017; Wang et al., 2009). Then, ER stress may induce the activation of the unfolded protein response and lead to alveolar epithelial cell apoptosis in cases of long-standing or severe activation (Chambers & Marciniak, 2014). In our study, the novel p.N207Y mutation was also identified in the carbohydrate-recognition domain (Figure 1i) and shown to induce ER stress and apoptosis in A549 cells. Our study further confirmed that mutations in the carbohydrate-recognition domain of SFTPA2 are associated with IPF. To date, only eight SFTPA2 mutations have been reported in IPF, lung cancer, and ILD patients (van Moorsel et al., 2015; Wang et al., 2009). We have reviewed all the mutations in Figure 1i.

The current methods for the diagnosis of IPF often involve chest HRCT and histology (Chung et al., 2016; Collard, 2017). In addition, all known causes of pulmonary fibrosis need to be excluded, such as connective tissue diseases, chronic hypersensitivity pneumonitis and asbestosis (Martinez & Flaherty, 2017). However, tissue biopsy of IPF patients is not easily to get and phenotypes of IPF patients in HRCT are sun-dry due to the effect of environmental exposure. Hence, the diagnosis of IPF is somehow difficult to determine. (Spagnolo & Cottin, 2017; Steele & Schwartz, 2013). Genetic sequencing and testing are effective and accurate measures for the diagnosis of IPF patients. Hence, genetic testing can further confirm a clinical diagnosis and allow genetic counseling of families with IPF (Petrovski et al., 2017). In our study, there was one member (III-2) in whom IPF could not be directly by clinical testing in the family. Our genetic research further confirmed that he was a mutation carrier, and genetic counseling was provided to this family.

In summary, we enrolled a family with IPF to explore the genetic mutation that they harbor by whole-exome sequencing. A novel mutation of SFTPA2 (NM_001098668.4: c.619A>T; NP_001092138.1: p.N207Y) was identified in the IPF patients and shown to co-separate in the affected members. Functional research further confirmed that this mutation can affect the secretion of the SFTPA2 protein and induce ER stress and apoptosis in A549 cells. Our study not only expands the spectrum of SFTPA2 mutations and contributes to the genetic diagnosis and counseling of IPF patients but also provides a valuable, population-specific SFTPA2 mutation that may contribute to further mechanistic and therapeutic research.

ACKNOWLEDGMENTS
The authors thank all the subjects for participating in this study. This study was supported by National Natural Science Foundation of China (81470202 and 81770002 to Hong Luo), the Science and Technology Program of Changsha, China (kq1901120 to Hong Luo) and the National Natural Science Foundation of China.

CONFLICT OF INTERESTS
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
Dr. Lv Liu performed the genetic analysis and molecular biology experiments including western blot and real-time PCR; Miss Jieli Qin conducted cell culture and cell transfection; Dr. Ting Guo enrolled clinical data of the family; Dr. Ping Chen, Dr. Ruoyun Ouyang and Dr. Hong Peng enrolled the samples and confirmed the diagnosis; Dr. Hong Luo and Dr. Lv Luo wrote and revised the manuscript. Dr. Hong Luo designed and supported the project. All authors approved the final manuscript.

DATA AVAILABILITY STATEMENT
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
REFERENCES

Armanios, M. Y., Chen, J. J., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., ... Loyd, J. E. (2007). Telomerase mutations in families with idiopathic pulmonary fibrosis. *New England Journal of Medicine*, 356(13), 1317–1326. https://doi.org/10.1056/NEJMo a066157

Becker, R. J. (1989). Physician-to-physician accountability aids UR. Interview by Mary T. Koska. *Hospitals*, 63(23), 57–60.

Chambers, J. E., & Marciniak, S. J. (2014). Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 2. Protein misfolding and ER stress. *American Journal of Physiology. Cell Physiology*, 307(8), C657–670. https://doi.org/10.1152/ajpcell.00183.2014

Chung, J. H., Peljto, A. L., Chawla, A., Talbert, J. L., McKean, D. F., Rho, B. H., ... Lynch, D. A. (2016). CT imaging phenotypes of pulmonary fibrosis in the MUC5B promoter site polymorphism. *Chest*, 149(5), 1215–1222. https://doi.org/10.1016/j.chest.2015.11.009

Collard, H. R. (2017). Improving survival in idiopathic pulmonary fibrosis: The race has just begun. *Chest*, 151(3), 527–528. https://doi.org/10.1016/j.chest.2017.01.007

Deng, Y., Li, Z., Liu, J., Wang, Z., Cao, Y., Mou, Y., ... Xiong, W. (2018). Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis. *Human Mutation*, 39(9), 1238–1245. https://doi.org/10.1002/humu.23566

Fernandez, B. A., Fox, G., Bhatia, R., Sala, E., Noble, B., Denic, N., ... Woods, M. O. (2012). A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: Clinical and genetic features. *Respiratory Research*, 13, 64. https://doi.org/10.1186/1465-9921-13-64

Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., ... Schwartz, D. A. (2013). Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nature Genetics*, 45(6), 613–620. https://doi.org/10.1038/ng.2609

Garcia-Sancho, C., Buendia-Roldan, I., Fernandez-Plata, M. R., Navarro, C., Perez-Padilla, R., Vargas, M. H., ... Selman, M. (2011). Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. *Respiratory Medicine*, 105(12), 1902–1907. https://doi.org/10.1016/j.rmed.2011.08.022

King, C. S., & Nathan, S. D. (2017). Idiopathic pulmonary fibrosis: Effects and optimal management of comorbidities. *The Lancet Respiratory Medicine*, 5(1), 72–84. https://doi.org/10.1016/S2213-2600(16)30222-3

Lawson, W. E., Crossno, P. F., Polosukhin, V. V., Roldan, J., Cheng, D. S., Lane, K. B., ... Blackwell, T. S. (2008). Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: Association with altered surfactant protein processing and herpesvirus infection. *American Journal of Physiology. Lung Cellular and Molecular Physiology*, 294(6), L1119–1126. https://doi.org/10.1152/ajplung.00382.2007

Lederer, D. J., & Martinez, F. J. (2018). Idiopathic pulmonary fibrosis. *New England Journal of Medicine*, 379(8), 797–798. https://doi.org/10.1056/NEJMct1807508

Liu, L., & Luo, H. (2018). Whole-exome sequencing identified a novel compound heterozygous mutation of LRRC6 in a Chinese primary ciliary dyskinesia patient. *BioMed Research International*, 2018, 1854269. https://doi.org/10.1155/2018/1854269

Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., ... Wells, A. U. (2017). Idiopathic pulmonary fibrosis. *Nature Reviews Disease Primers*, 3, 17074. https://doi.org/10.1038/nrdp.2017.74

Martinez, F. J., & Flaherty, K. R. (2017). Comprehensive and individualized patient care in idiopathic pulmonary fibrosis: Refining approaches to diagnosis, prognosis, and treatment. *Chest*, 151(5), 1173–1174. https://doi.org/10.1016/j.chest.2017.03.017

Nogee, L. M., Dunbar, A. E. 3rd, Wert, S., Askin, F., Hamvas, A., & Whitsett, J. A. (2002). Mutations in the surfactant protein C gene associated with interstitial lung disease. *Chest*, 121(3 Suppl), 208–215. https://doi.org/10.1378/chest.121.3_suppl.208

Petrovski, S., Todd, J. L., Durheim, M. T., Wang, Q., Chien, J. W., Kelly, F. L., ... Goldstein, D. B. (2017). An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, 196, 82–93. https://doi.org/10.1164/rccm.201610-2080OC

Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., ... Schünemann, H. J. (2011). An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine*, 183(6), 788–824. https://doi.org/10.1164/rccm.2009-040GL

Richeldi, L., Collard, H. R., & Jones, M. G. (2017). Idiopathic pulmonary fibrosis. *Lancet*, 389(10082), 1941–1952. https://doi.org/10.1016/S0140-6736(17)30866-8

Selman, M., Lin, H. M., Montano, M., Jenkins, A. L., Estrada, A., Lin, Z., ... Floros, J. (2003). Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. *Human Genetics*, 113(6), 542–550. https://doi.org/10.1007/s00439-003-1015-4

Shulenin, S., Nogee, L. M., Annilo, T., Wert, S. E., Whitsett, J. A., & Dean, M. (2004). ABCA3 gene mutations in newborns with fatal surfactant deficiency. *New England Journal of Medicine*, 350(13), 1296–1303. https://doi.org/10.1056/NEJMoa032178

Silveyra, P., & Floros, J. (2013). Genetic complexity of the human surfactant-associated proteins SP-A1 and SP-A2. *Gene*, 531(2), 126–132. https://doi.org/10.1016/j.gene.2012.09.111

Spagnolo, P., & Cottin, V. (2017). Genetics of idiopathic pulmonary fibrosis: From mechanistic pathways to personalised medicine. *Journal of Medical Genetics*, 54(2), 93–99. https://doi.org/10.1136/jmedgenet-2016-103973

Steele, M. P., & Schwartz, D. A. (2013). Molecular mechanisms in progressive idiopathic pulmonary fibrosis. *Annual Review of Medicine*, 64, 265–276. https://doi.org/10.1146/annurev-med-042711-142004

Stuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., ... Garcia, C. K. (2015). Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. *Nature Genetics*, 47(5), 512–517. https://doi.org/10.1038/ng.3278

van Moorsel, C. H., Ten Klooster, L., van Oosterhout, M. F., de Jong, P. A., Adams, H., Wouter van Es, H., ... Grutters, J. C. (2015). SFTPA2 Mutations in Familial and Sporadic Idiopathic Interstitial Pneumonia. *American Journal of Respiratory and Critical Care Medicine*, 192(10), 1249–1252. https://doi.org/10.1164/rccm.201510-4067LE

Vulliamy, T., Marrone, A., Szydlo, R., Walne, A., Mason, P. J., & Dokal, I. (2004). Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. *Nature Genetics*, 36(5), 447–449. https://doi.org/10.1038/ng.1346
Wang, Y., Kuan, P. J., Xing, C., Cronkhite, J. T., Torres, F., Rosenblatt, R. L., ... Garcia, C. K. (2009). Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. *American Journal of Human Genetics*, 84(1), 52–59. https://doi.org/10.1016/j.ajhg.2008.11.010

**SUPPORTING INFORMATION**

Additional Supporting Information may be found online in the Supporting Information section.

---

**How to cite this article:** Liu L, Qin J, Guo T, et al. Identification and functional characterization of a novel surfactant protein A2 mutation (p.N207Y) in a Chinese family with idiopathic pulmonary fibrosis. *Mol Genet Genomic Med*. 2020;8:e1393. https://doi.org/10.1002/mgg3.1393